CRISPR Therapeutics AG (CRSP) Receivables - Other (2016 - 2024)

CRISPR Therapeutics AG has disclosed Receivables - Other across 9 years of filings, most recently posting $2.1 million for Q4 2024.

• Receivables - Other for Q4 2024 came in at $2.1 million, down 67.69% year-over-year; the trailing twelve-month figure through Dec 2024 was $2.1 million (down 67.69% YoY), and the FY2024 annual result was $2.1 million, down 67.69% from the prior year.
• Receivables - Other came in at $2.1 million for Q4 2024 at CRISPR Therapeutics AG, down from $6.5 million in the prior quarter.
• In the past five years, Receivables - Other ranged from a high of $25.0 million in Q1 2020 to a low of $2.1 million in Q4 2024.
• The 5-year median for Receivables - Other is $11.0 million (2020), against an average of $14.2 million.
• Across the five-year window, Receivables - Other surged 64002.56% in 2020 and tumbled 67.69% in 2024, its largest moves.
• CRISPR Therapeutics AG's Receivables - Other stood at $10.7 million in 2020, then declined by 21.5% to $8.4 million in 2021, then surged by 33.33% to $11.2 million in 2022, then slumped by 41.96% to $6.5 million in 2023, then sank by 67.69% to $2.1 million in 2024.
• The last three Receivables - Other figures came in at $2.1 million (Q4 2024), $6.5 million (Q4 2023), and $11.2 million (Q4 2022), per Business Quant data.